logo
  • Global Challenge
  • Our Approach
  • Partnering
  • Pipeline
  • Join Us
  • News & Events
  • Investors
    • Company Information
    • Board and Management
    • Advisors
    • Investor Alert
  • Publications
  • Contact

World Antibiotic Awareness Week Video

November 18, 2019
|In Alderley Park, News, Publications
|By Carl Curran

 

 

  • Prev
  • All Stories
  • Next

Related News

Infex to present webinar on broader pipeline and growth strategy

Infex Therapeutics, a leading anti-infectives specialist, announces it will be holding a…

StickyEvents,Press Releases,Breaking News,Pipeline

Infex Therapeutics written submission to the Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria (PACCARB)

Events,Breaking News

Infex Therapeutics announces positive Phase IIa results for RESP-X in non-cystic fibrosis bronchiectasis patients colonised with Pseudomonas aeruginosa

Infex Therapeutics, a leading anti-infectives specialist, today announced positive…

Press Releases,Breaking News,Pipeline

Infex Therapeutics secures £4.3 million funding to advance anti-infective pipeline targeting drug-resistant infections

Investment led by Jon Moulton supports progression of clinical and preclinical programmes…

Events,Press Releases,Breaking News

World AMR Awareness Week 2025

This World AMR Awareness Week, we're proud to be celebrating our collaboration with…

Events,Breaking News

UK Government investment is vital to combat AMR

As the world wakes to the reality of the crisis posed by antimicrobial resistance (AMR),…

Press Releases,Breaking News

Infex agrees collaboration with Asian clinical trials network, ADVANCE-ID

Memorandum of Understanding signed to investigate hospital-acquired drug-resistant…

Press Releases,Breaking News,Pipeline

Infex signs exclusive license agreement with Venus Remedies Ltd to advance MET-X through clinical development and commercialisation in India

Infex Therapeutics, a leading anti-infectives specialist, announces that it has signed an…

Press Releases,Breaking News,Pipeline

Infex and Justus-Liebig-University Giessen awarded £1 million grant from PACE

Grant to develop first-in-class antimicrobial drug targeting multi-drug-resistant…

Press Releases,Breaking News,Pipeline

First NCFB patient dosed in Phase IIa study of RESP-X

Potential first-in-class anti-virulence antibody drug to reduce the frequency of…

Press Releases,Breaking News,Pipeline

© Infex Therapeutics Ltd. All rights reserved.